Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.52 |
| ▸ | MAOA | P21397 | 9/20 | 0.52 |
| ▸ | TLR4 | O00206 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810695 | 0.89 | MAPT (0.58) | MAOBTLR4TLR2APPSMN1; SMN2 | |
| SCHEMBL810159 | 0.89 | MAOB (0.50) | MAOBMAOATLR4TLR2APP | |
| SCHEMBL810233 | 0.89 | SIRT2 (0.50) | MAOBMAOAAPPSMN1; SMN2MAPT | |
| SCHEMBL811395 | 0.89 | MAOB (0.50) | MAOBMAOASMN1; SMN2LMNANPSR1 | |
| SCHEMBL810842 | 0.88 | MEN1 (0.53) | MAOBMAOATLR4TLR2SMN1; SMN2 | |
| SCHEMBL29463873 | 0.88 | MEN1 (0.53) | MAOBMAOATLR4TLR2SMN1; SMN2 | |
| SCHEMBL6643739 | 0.86 | MAOB (0.50) | MAOBMAOATLR4TLR2APP | |
| SCHEMBL5064909 | 0.85 | BCL2 (0.46) | MAOBMAOASMN1; SMN2LMNABCL2 | |
| SCHEMBL811221 | 0.85 | APP (0.49) | MAOBAPPSMN1; SMN2LMNANPSR1 | |
| SCHEMBL810308 | 0.85 | VCAM1 (0.61) | MAOBMAOASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1642895-B1 | Novel substituted naphthopyrans | TRANSITIONS OPTICAL INC (US) | 2010-03-31 | — | — | EP | disclosed |
| CN-101384592-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1642895-A2 | Novel substituted naphthopyrans | TRANSITIONS OPTICAL, INC. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-5651923-A | PHOTOCHROMIC ARTICLE | TRANSITIONS OPTICAL, INC. (US) | 1997-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAOB 3352/4885MAOA 3771/4885TLR4 1341/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | MAOB 3352/4885MAOA 3771/4885TLR4 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.